SHARE

News Alert: Citius Pharmaceuticals Receives FDA Approval For LYMPHIR™ (Denileukin Diftitox-Cxdl) Immunotherapy For The Treatment Of Adults With Relapsed Or Refractory Cutaneous T-Cell Lymphoma. Click to Read More.

A day after Pharmacyte Biotech Inc (OTCMKTS:PMCB) announced the completion of its International Consortium, Goldman Small Cap Research showed up with another sponsored research report for the company. This is Goldman’s second research report on the company within a span of few days. It is to be noted that Goldman Small Cap Research specializes in analyzing micro companies.

The new report

In its report, analyst Rob Goldman discussed how the company gathered a team of elite members and thus, set the stage to progress towards conducting human clinical trials for diabetes and cancer. Goldman gave a detailed account on how Pharmacyte Biotech Inc (OTCMKTS:PMCB)’s CEO Kenneth L. Waggoner has been able to upgrade the quality of his team. He briefed that invaluable human capital has been sourced for the clinical research and execution.

Pointing to the Pharmacyte Biotech Inc (OTCMKTS:PMCB)’s recently formed 16-member International Consortium, Goldman noted that the team includes members who have expertise on both diabetes and cancer treatments. He made a note that each of the members of the Consortium holds an extensive experience in diabetes research, whereas work of many of them has featured in some of the renowned scientific journals.

Latest developments

Goldman did not miss to mention that one of the members, Prof. Ann M Simpson, has already established the fact that Melligen cells encapsulated using the company’s technology are effective enough to reverse Type 1 Diabetes. If the company’s technology, ‘Cell-In-A-Box’ attains similar result in human trials then it has the potential to replace insulin-based diabetes treatment, which accounts $176 billion of the market in the U.S.

Pharmacyte Biotech Inc (OTCMKTS:PMCB)’s Waggoner has previously informed that their International Consortium is complete following the addition of Dr. Thomas Stratmann and Dr. Axel Kornerup Hansen. The news led the stock price of the company during the last trading session, where it surged by nearly 5% to $0.173 as 4.84 million shares traded hands.

SHARE
Previous articleOSL Holdings Inc (OTCMKTS:OSLH)’s Earth Day Announcement Failed To Impress
Next articleAnavex Life Sciences Corp (OTCMKTS:AVXL) Participates In World Orphan Drug Congress
Steve Kanaval
Steve Kanaval: Portfolio Manager/Writer/ Market Analyst Steve began his career in the Trading Pits in Chicago making markets at the Chicago Mercantile Exchange (NYSE:CME) the Chicago Board of Trade and the CBOE in the early 80’s. He ran the Morgan Stanley Derivative Prop Trading for the firm specializing in Index Arbitrage. He continued his career as a Trader/Portfolio Manager for multiple Hedge Funds during the Internet Boom of the 90’s managing large portfolios. Steve is known as an expert in MicroCap Technology Stocks and the emerging Digital Currency markets as a Portfolio Manager for his Family Office. Steve has managed portfolio’s in volatile asset classes for 3 decades as a commodity trader, hedge fund manager and digital currency trader and miner. Steve publishes his views on the asset classes in a public forum and has published more than 10,000 articles simplifying these complex and volatile assets for readers. His work is published on multiple sites including Bloomberg, Equities.com, Hacked.com, CryptoCurrencyNews as a paid contributor. His work includes research, journalism and archived video on important market volatility related to stocks, digital currency and other volatile misunderstood asset classes. He offers a humorous, unique insight and the related back stories and drivers for readers interested in volatility and emerging market assets. Full disclosure Steve is long 25 digital currencies and sits on the board of multiple public companies involved in digital currencies, and owns shares in these companies from time to time.